Patients burned by coverage denials and mid-year formulary changes are no longer assuming that insurance is the only legitimate way to pay for care
Key Phase 3 trials include: TRIUMPH-1: Retatrutide for obesity without type 2 diabetes TRIUMPH-2: Retatrutide for type 2 diabetes TRIUMPH-3: Retatrutide for obesity with type 2 diabetes TRIUMPH-4: Retatrutide for metabolic dysfunction-associated steatohepatitis (MASH) Results from these trials are expected between 2025 and 2027
For those who have suffered conditions like gastroparesis, bowel rupture, or permanent vision loss, this category of compensation can be substantial
"Their brain is constantly telling their body that they don't have enough They don't have enough fuel
They do tap into the GABAergic pathway, neurotransmitter folks, that, in general, broad sweeping generalization here, can have somewhat of a sedative quality, which is why I take magnesium threonate and/or bisglycinate before sleep, 30 to 60 minutes before sleep
GLP-1 receptor agonists such as Saxenda and Wegovy work, with clinical trial evidence behind them roughly 6% and 16% body weight reduction respectively over 68-week trials